Perimeter Medical Imaging AI Delivers Outstanding Third Quarter Performance
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) has recently reported its financial results for the third quarter of the year, showcasing remarkable achievements that underline its progress in the medical technology sector. The Company is advancing well with its S-Series imaging devices, which have gained significant traction in the marketplace.
Strong Financial Results Amidst Seasonal Challenges
Even with typical seasonal fluctuations, Perimeter experienced substantial revenue growth. The Q3-2025 revenue of $536,000 reflected an impressive increase of 157% year-over-year compared to the same quarter in 2024. This growth is indicative of the Company’s robust market strategy and the increasing adoption of its advanced imaging systems.
In fact, the total revenue for the first nine months of 2025 exceeded $1.6 million, marking an 88% rise compared to all of 2024. Additionally, the Company achieved a significant reduction in operating expenses, with a 34% decrease year-over-year and a 30% reduction sequentially. Such efficiencies combined with strong sales results have placed Perimeter on solid financial footing.
CEO Reflects on Progress and Future Goals
Adrian Mendes, the CEO of Perimeter, expressed optimism regarding the trajectory of the business. "The strong business momentum from the second quarter carried through the third quarter, reinforcing the traction we are building," Mendes stated. He emphasized the role of the S-Series in improving surgical outcomes and the anticipation surrounding the forthcoming B-Series, which is expected to revolutionize cancer surgery practices.
Growth of the S-Series Imaging Technology
Perimeter’s S-Series OCT device is at the forefront of the Company’s offerings, having been cleared by the FDA for use in various medical settings. This innovative system is designed to deliver real-time imaging capabilities that enhance surgical decision-making. It has already been employed by surgeons to visualize excised tissues across more than 3,500 patients, reflecting a 17% increase since August.
Furthermore, Perimeter recently made strides in expanding usage in reputable medical facilities, such as Medical City Dallas Hospital, which participated in a pivotal clinical trial for the next-generation B-Series device.
Insights from Clinical Engagements
Interestingly, Dr. Amelia Tower, a prominent breast surgical oncologist, shared insights on the utility of the S-Series at the Annual Clinical Assembly of the American College of Osteopathic Surgeons. Presenting at such esteemed gatherings underscores the role of the S-Series in enhancing cancer margin visualization during surgeries.
Progress on the Next-Generation B-Series Device
The Company is also making significant headway with the upcoming Perimeter B-Series, which merges advanced AI technology with OCT systems. Regulatory collaboration with the FDA is ongoing, and the Company is optimistic about receiving approval in the near future. The introduction of the OCT-Tissue Surveillance Registry is another stride towards optimizing product development, leveraging data collected from surgical procedures.
Perimeter’s commitment to innovation was further highlighted with the recent appointment of Dr. Ted James as Chief Medical Officer, supporting the commercialization efforts of the B-Series. This strategic hiring reflects Perimeter's focus on bolstering its leadership team to ensure successful growth initiatives.
Company’s Strategic Developments and Future Outlook
Corporate growth strategies have been reinforced through recent appointments of key personnel in important roles. Abbey Goodman and Paolo DiPasquale have joined the team with a mission to drive sales growth and align the Company’s direction with market demands. Additionally, the establishment of the Perimeter Industry Advisory Board promises to provide strategic insights from seasoned professionals to navigate the complex medical technology landscape.
As of the latest financial reports, Perimeter had approximately $1.7 million in cash, providing a solid financial runway for upcoming projects and initiatives.
Engaging with Stakeholders
Today, Perimeter will host a conference call to discuss its Q3 results and future growth strategies. Stakeholders are encouraged to participate in this informative session that will provide them with insights into the Company’s operational progress and strategic priorities.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto and Dallas, Perimeter Medical Imaging AI stands out as a medical technology firm dedicated to enhancing cancer surgery. With its ultra-high-resolution imaging tools, the Company focuses on addressing significant medical challenges. The FDA-cleared S-Series system exemplifies its commitment to transforming patient outcomes, while the investigational B-Series aims to push the envelope further in surgical medicine.
Frequently Asked Questions
What are the key financial results reported for Q3 2025?
The Company reported Q3 revenues of $536,000, a 157% increase from Q3 2024, and a significant reduction in operating expenses.
What technological advancements are included in the S-Series?
The S-Series provides real-time, cross-sectional imaging of excised tissues, enhancing surgical decision-making.
When is the anticipated regulatory decision for the B-Series?
Perimeter expects a regulatory decision regarding the B-Series in the first half of 2026.
Who has been appointed to key positions within the Company?
Abbey Goodman and Paolo DiPasquale have been named Vice Presidents to champion sales growth.
How does Perimeter plan to advance its product portfolio?
Through strategic partnerships, expert appointments, and innovative registries, the Company aims to enhance its products continually.
